XTLB
Live News • Jul 01
XTL Biopharmaceuticals Acquires Psyga Bio to Focus Fully on Psychedelic Medicines XTL Biopharmaceuticals has completed its acquisition of Psyga Bio Ltd., making psychedelic operations its exclusive core business and adding clinical pipelines, a licensed pharmaceutical manufacturing facility and a proprietary IP library focused on psychedelic treatments for severe mental health disorders.
The deal gives XTL Biopharmaceuticals direct control over both research and development (R&D) and licensed production capacity in psychedelic medicine, which could influence how quickly it can move treatments through clinical development and into potential commercialization.
XTL Biopharmaceuticals’ shares last traded at ₪0.02, with the stock down 18.2% year to date.
This shift turns XTL Biopharmaceuticals into a focused psychedelic medicine company, concentrating both the potential upside and the risk on one emerging therapeutic area and on the company’s ability to advance and protect its psychedelic-related clinical and manufacturing assets. Announcement • May 02
XTL Biopharmaceuticals Ltd. announced delayed 20-F filing On 04/30/2026, XTL Biopharmaceuticals Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Announcement • Apr 30
XTL Biopharmaceuticals Ltd. (TASE:XTLB) entered into a definitive share purchase agreement to acquire Psyga Bio Ltd from the current shareholders. XTL Biopharmaceuticals Ltd. (TASE:XTLB) entered into a definitive share purchase agreement to acquire Psyga Bio Ltd from the current shareholders on April 28, 2026. Pursuant to the Purchase Agreement, XTL Biopharmaceuticals will acquire from the current shareholders of Psyga all of the issued and outstanding share capital of Psyga on a fully diluted basis in exchange for the issuance by XTL Biopharmaceuticals to the current shareholders of Psyga, by way of a private placement, of such number of ADSs of the Company representing, immediately after such issuance, 40% of the issued and outstanding share capital of XTL Biopharmaceuticals. In addition, as part of the Transaction, the shareholders of Psyga will be issued additional ADSs representing 10% of the issued and outstanding share capital of the Company as of the effective date of the Purchase Agreement upon the achievement of each of three (3) milestones (each, a “Milestone”): (i) the commencement of at least three (3) clinical trials with human patients of certain products from Psyga’s pipeline within twelve (12) months following the closing of the Transaction; (ii) the successful achievement of targets in at least two (2) clinical trials with human patients of certain products from Psyga’s pipeline within thirty-six (36) months following the closing of the Transaction; and (iii) entering the development of Ibogaine-based products triggered by execution of a binding commercialization agreement and/or development partnership agreement with a reputable third-party pharmaceutical, biotechnology, or life sciences company for the commercialization, licensing, development and/or co-development of Ibogaine-based products based on the Company’s regulatory licenses.
XTL Biopharmaceuticals's audit committee and board of directors approved the Transaction. The Purchase Agreement contains customary representations and warranties, agreements and obligations and conditions to closing, all as are customary for transactions of this nature, including, without limitation, the approval of the Transaction by the Company’s shareholders and receipt of necessary government or third-party approvals, if required.
I.F.S. Consulting and Investments Ltd acted as fairness opinion provider for XTL Biopharmaceuticals Ltd. Ronen Kantor of Amit, Pollak, Matalon & Co. acted as legal advisor for XTL Biopharmaceuticals Ltd. Yariv Reichenberg of Weksler, Bregman & Co. Advocates acted as legal advisor for Psyga Bio Ltd. 
